Aviva PLC increased its stake in Laboratory Corporation of America Holdings (NYSE:LH) by 1.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,377 shares of the medical research company’s stock after buying an additional 1,050 shares during the period. Aviva PLC owned 0.06% of Laboratory Corporation of America Holdings worth $9,923,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Laboratory Corporation of America Holdings by 2.6% in the first quarter. Vanguard Group Inc. now owns 10,130,291 shares of the medical research company’s stock worth $1,453,393,000 after buying an additional 259,182 shares during the period. BlackRock Inc. boosted its stake in Laboratory Corporation of America Holdings by 3,602.5% in the first quarter. BlackRock Inc. now owns 8,074,378 shares of the medical research company’s stock worth $1,158,430,000 after buying an additional 7,856,297 shares during the period. State Street Corp boosted its stake in Laboratory Corporation of America Holdings by 2.4% in the first quarter. State Street Corp now owns 4,639,813 shares of the medical research company’s stock worth $665,669,000 after buying an additional 109,170 shares during the period. Boston Partners boosted its stake in Laboratory Corporation of America Holdings by 4.8% in the second quarter. Boston Partners now owns 4,590,372 shares of the medical research company’s stock worth $707,560,000 after buying an additional 210,138 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in Laboratory Corporation of America Holdings by 0.4% in the first quarter. Bank of New York Mellon Corp now owns 1,347,599 shares of the medical research company’s stock worth $193,340,000 after buying an additional 5,743 shares during the period. 93.19% of the stock is currently owned by institutional investors.

Laboratory Corporation of America Holdings (LH) opened at 154.77 on Monday. The firm has a 50-day moving average of $156.06 and a 200-day moving average of $145.76. The stock has a market capitalization of $15.76 billion, a price-to-earnings ratio of 21.68 and a beta of 0.94. Laboratory Corporation of America Holdings has a 1-year low of $119.51 and a 1-year high of $164.22.

Laboratory Corporation of America Holdings (NYSE:LH) last posted its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.40 by $0.07. The business had revenue of $2.50 billion during the quarter, compared to analysts’ expectations of $2.47 billion. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period last year, the company posted $2.36 earnings per share. Equities research analysts anticipate that Laboratory Corporation of America Holdings will post $9.51 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/28/aviva-plc-has-9-92-million-stake-in-laboratory-corporation-of-america-holdings-lh.html.

A number of equities research analysts have recently commented on LH shares. Credit Suisse Group restated a “buy” rating and set a $146.00 target price on shares of Laboratory Corporation of America Holdings in a research report on Sunday, May 28th. ValuEngine lowered shares of Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Saturday, June 3rd. BidaskClub lowered shares of Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Barclays PLC reaffirmed an “overweight” rating and issued a $182.00 price target (up from $175.00) on shares of Laboratory Corporation of America Holdings in a research note on Monday, July 17th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $179.00 price target (up from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Thursday, July 27th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $159.75.

In other Laboratory Corporation of America Holdings news, Director R Sanders Williams sold 3,100 shares of Laboratory Corporation of America Holdings stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $156.88, for a total value of $486,328.00. Following the completion of the sale, the director now directly owns 10,073 shares in the company, valued at $1,580,252.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Glenn A. Eisenberg sold 5,968 shares of Laboratory Corporation of America Holdings stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $159.46, for a total transaction of $951,657.28. Following the completion of the sale, the chief financial officer now owns 18,122 shares of the company’s stock, valued at $2,889,734.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 14,068 shares of company stock valued at $2,237,985. 0.90% of the stock is currently owned by corporate insiders.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corporation of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Stock Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related stocks with our FREE daily email newsletter.